Amgen stock price prediction: Double-digit sales growth strengthens rally outlook

Traders Union
All News
Stocks
Amgen jumps 4.02% on earnings boost

Highlights

Amgen stock gained momentum after reporting second-quarter revenue growth of 10% to $10.1 billion and a 65% increase in GAAP earnings per share to $4.37.
Product sales rose 9% with 22 medicines posting double-digit gains, and six core drugs delivered nearly 70% of product revenue.
Shares of Amgen trade above key moving averages with a bullish structure; the price is forecast between $434.99 and $450.03, though short-term pullbacks are possible due to overbought readings.

Robust earnings and product sales fuel investor momentum amid research exit

Amgen reported second-quarter revenue growth of 10% to $10.1 billion and a 65% rise in GAAP earnings to $4.37 per share, with Data from Finance Yahoo highlighting product sales up 9%. This strong financial performance reflects robust expansion and margin gains, fueling investor demand and supporting strong price momentum. The company also detailed that twenty-two of its medicines achieved double-digit sales increases, while six key products contributed nearly 70% of product revenue, emphasizing broad portfolio strength. In a secondary development, Tipranks reported that TScan Therapeutics announced Amgen is set to terminate a Crohn's disease research collaboration effective November 10, 2026, though this has a more limited near-term impact compared to the earnings drivers.

Bullish momentum capped by overbought signals and diverging indicators

On the technical side, AMGN is trading above the MA-20 ($426.75) and MA-50 ($419.9) on the H1 chart, as well as well above the MA-200 ($350.68) on the daily timeframe. Immediate support is identified at the Ichimoku Kijun level of $426.12. Momentum indicators on the H1 chart remain bullish, with both MACD and ADX signaling continued buying pressure. However, RSI at 76.26 and CCI readings indicate overbought conditions, while Stochastic RSI is suggesting the potential for a downside retracement. Buyers are still in control intraday, as shown by Bull/Bear Power dominance, though the Awesome Oscillator is currently neutral, and several momentum indicators are diverging, which highlights the potential for pullbacks.

Sideways or upside bias persists as breakout and reversal risks diverge

In the short term, the most likely scenario sees AMGN ranging between $434.99 and $450.03, consistent with typical volatility for the current environment. The probability of further gains is 71%, favoring sideways or continued upside movement, while a reversal lower is less likely at 29%. A breakout above resistance could trigger a renewed uptrend, while a close below support at the Kijun level would raise the risk of deeper corrective action.

Anton Kharitonov, expert at Traders Union, sees Amgen’s technical setup as broadly positive but short-term risks stand out. He notes strong fundamental drivers, but overbought momentum and indicator divergences call for caution. Immediate price levels between $434.99 and $450.03 should be watched closely, with the Kijun support level as a tactical pivot. "Despite solid business growth, I remain cautious here until technical signals confirm sustained strength above key supports."

Earlier, analysts noted that Amgen maintained a bullish technical outlook, underpinned by strong fundamentals and positive momentum signals. The current article reinforces this view with fresh evidence of robust earnings growth and broad portfolio performance, while traders should monitor price action near the $434.99–$450.03 range for signs of a potential breakout or corrective pullback.

Source of Data: AMGN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.